Astra Drug Improves Survival by Half in Early Stage Lung Cancer.

This data is important because it's "bringing a precision medicine into an early stage of lung cancer." (Bloomberg) -- A blockbuster lung cancer drug from AstraZeneca Plc was found to improve survival by more than half in a subset of patients, boosting the company's ambitions to widen its oncology portfolio across as many groups and indications as possible. [Extracted from the article]